Table 1.
Clinical trails on carbon ion radiotherapy at GHMC.
| Trial ID | Patient enrollment | Cancer type | Major indication criteria | Total dose/fr. | Combined therapy |
|---|---|---|---|---|---|
| Gunma0905 | 2012- | Cranial base tumor | No CNS invasion | 60.8 GyRBE/16 fr. | – |
| Gunma0901 | 2010–2013 | H&N cancer (except Sq, melanoma, sarcoma) | N0/1M0 | 57.6 or 64 GyRBE/16 fr. | – |
| Gunma0902 | 2012- | H&N musculoskeletal tumor | N0/1M0 | 70 GyRBE/16 fr. | – |
| Gunma0903 | 2012- | H&N melanoma | N0M0 | 57.6 or 64 GyRBE/16 fr. | Concurrent DTIC, ACNU, and VCR |
| Gunma0701 | 2010–2015 | NSCLC | Stage I, peripheral, inoperable | 60 GyRBE/4 fr. | – |
| Gunma1201 | 2013–2015 | NSCLC | Stage III, inoperable | 40 GyRBE/10 fr. (ENI) + 20 or 24 GyRBE/6 fr. (IFI) | – |
| Gunma0703 | 2010–2013 | Hepatcellular carcinoma | Tumor diameter ≤10 cm | 52.8 GyRBE/4 fr. | – |
| Gunma1203 | 2013 | Hepatcellular carcinoma | Tumor diameter 3–10 cm | 60 GyRBE/4 fr. | – |
| Gunma1303 | 2013–2015 | Hepatcellular carcinoma | Adjacent to digestive tract | 60 or 64.8 GyRBE/12 fr. | – |
| Gunma1301 | 2013–2015 | Pancreatic cancer | T4N0/1, inoperable | 52.8 or 55.2 GyRBE/12 fr. | Concurrent gemcitabine |
| Gunma1501 | 2015- | Pancreatic cancer | T4N0/1M0 | 55.2 GyRBE/12 fr. | Concurrent S-1 |
| Gunma0801 | 2010- | Rectal cancer | Postoperative local recurrence | 73.6 GyRBE/16 fr. | – |
| Gunma0702 | 2010–2013 | Prostate cancer | ≤T3 | 57.6 GyRBE/16 fr. | ± Hormone therapy |
| Gunma1302 | 2013- | Prostate cancer | ≤T3 | 57.6 GyRBE/16 fr. | ± Hormone therapy |
| Gunma1103 | 2013- | Prostate cancer | Castration resistant cancer | 57.6 GyRBE/16 fr. | ± Hormone therapy |
| Gunma1202 | 2013–2014 | Uterine cervical cancer | Locally advanced | 36 GyRBE/12 fr. (WPI) + 19.2 GyRBE/4 fr. (IFI) | Concurrent CDDP followed by ICBT |
| Gunma1401 | 2014- | Uterine cervical cancer | Locally advanced | 36 GyRBE/12 fr. (WPI) + 19.2 GyRBE/4 fr. (IFI) | Concurrent CDDP followed by ICBT |
| Gunma0904 | 2010–2013 | Musculoskeletal tumors | N0M0 | 64, 67.2, or 70.4 GyRBE/16 fr. | – |
| Gunma1102 | 2011–2013 | Musculoskeletal tumors (pediatric) | Age 6–16, inoperable | 60.8, 64, 67.2, or 70.4 GyRBE/16 fr. | – |
| Gunma1101 | 2011- | Lymph node metastatic tumor | 1–3 nodes in 1 irradiation field | 48 or 52.8 GyRBE/12 fr. | – |
| Gunma1304 | 2013- | In-field recurrent tumor | previously treated by radiotherapy | Various according to disease site | – |
| Gunma1204 | 2013- | Tumor resistant to standard Tx | known to be resistant to standard Tx | Various according to disease site | – |
fr., fractions; CNS, central nervous system; H&N, head and neck; Sq, squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; DTIC, dacarbazine; ACNU, nimustine; VCR, vincristine; ENI, elective nodal irradiation; IFI, involved field irradiation; WPI, whole pelvic irradiation; CDDP, cisplatin; ICBT, intracavitary brachytherapy; Tx, therapy.